278
Participants
Start Date
September 30, 2007
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
ABT-089
Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
atomoxetine
Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
placebo
Subject will take a tablet once daily for 8 weeks
Site Reference ID/Investigator# 5998, Herndon
Site Reference ID/Investigator# 5994, Charleston
Site Reference ID/Investigator# 5995, Jacksonville
Site Reference ID/Investigator# 5977, Orlando
Site Reference ID/Investigator# 5993, Bradenton
Site Reference ID/Investigator# 5976, Memphis
Site Reference ID/Investigator# 5983, Middleton
Site Reference ID/Investigator# 5981, Northbrook
Site Reference ID/Investigator# 5982, Overland Park
Site Reference ID/Investigator# 5992, Omaha
Site Reference ID/Investigator# 5999, Little Rock
Site Reference ID/Investigator# 6000, Austin
Site Reference ID/Investigator# 5986, Boulder
Site Reference ID/Investigator# 5997, Las Vegas
Site Reference ID/Investigator# 5979, El Centro
Site Reference ID/Investigator# 5984, Portland
Site Reference ID/Investigator# 5980, Salem
Site Reference ID/Investigator# 5996, Eugene
Site Reference ID/Investigator# 5978, Bellevue
Site Reference ID/Investigator# 5987, Clementon
AbbVie (prior sponsor, Abbott)
INDUSTRY